[Treatment results of chemotherapy with S-1 for head and neck cancer].
A study of chemotherapy treatment with S-1 in patients with head and neck cancer was conducted in 20 patients with residual tumor after primary chemoradiotherapy, or recurrent tumors. Treatment courses consisted of oral administration of S-1 at a dose of 80 to 120 mg/day depending on the body surface area for 14 consecutive day followed by a 7- day rest period. The response rate in patients with residual tumors after primary chemoradiotherapy was 55.6%(5/9). In patients with recurrent tumors, the response rate was 0%(0/11), however, median survival time was 534.5 days. Therefore, S-1 seemed to be useful for the treatment of patients with head and neck cancer from the point of QOL.
Shirasaki
Takashi
T
Dept. of Otolaryngology, Hirosaki University School of Medicine.
Maruya
Shin-ichiro
S
Namba
Atsushi
A
Matsubara
Atsushi
A
Shinkawa
Hideichi
H
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000009:adverse effects / Q000627:therapeutic use*; D005641:Tegafur / Q000009:adverse effects / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid